Business Sweden in cooperation with the Embassy of Sweden in China would like to invite you to participate in a delegation on the topic "Innovative Solutions for Efficient Cancer Management" in Beijing June 10-11, 2014. The overall objective is to build a Chinese - Swedish platform for business dialogue.
In 2006 Sweden and China signed a Memorandum of Understanding (MoU) on cooperation within health care. During the Swedish Minister for Health’s visit to China in 2010 an Action Plan was signed specifying seven areas of cooperation between China and Sweden of which one is cancer management. The Swedish Minister for Health once again visited his counterpart in China in April 2013 and discussions on the topics cancer care, infection control, primary care versus advanced hospitals as well as elderly care were held during seminars and meetings in Beijing and Shanghai. With this cancer management delegation to Beijing we aim to continue the dialogue and cooperation around cancer management. The delegation is part of 2014’s Swedish Life Science cluster activity in China.
Purpose of Delegation
The purpose of the delegation is to:
Increase awareness and visibility among care providers, key opinion leaders, and decision makers in Beijing
Strengthen the dialogue and exchange experiences between China and Sweden regarding challenges and solutions within cancer management as well as to further strengthen Sweden’s position within the area
Create a platform for inspiration and concrete outcome like business relations and network building
Cancer in China
Yearly, approximately 2.2 million Chinese citizens are diagnosed with cancer and 1.6 million die from the disease. A 2008 national mortality survey estimate that cancer accounts for 25% of deaths in urban areas of China and 21% of deaths in rural area. The growing burden of cancer in China is due to several factors such as an ageing population, dietary changes, environmental hazards, certain infectious diseases associated with cancer, and smoking. Lung cancer has become the most common cause of cancer-related death in China, but liver, stomach and oesophageal cancer are the next most deadly cancers in China. It is expected that China could have 1 million lung cancer patients by 2025. Due to the development of cancer in China cancer is becoming a national priority.
Access to Key Stakeholders
The platform gives access to the most relevant Chinese target groups:
- Chinese care providers (e.g. radiotherapy specialists, oncologists, physicists)
- Representatives from relevant authorities (e.g. MoH, CFDA)
- Research institutions and industry organizations
- Patient organizations
Registration of Interest
Does this sound interesting for your company? Register below and we will get back to you with more information for participation. Registration below is not binding at this stage.
Andrea Staxberg, Project Manager, Business Sweden Shanghai
Phone: +86 21 6218 9955
In cooperation with: